Publication | Closed Access
Interferon signature guiding therapeutic decision making: ruxolitinib as first-line therapy for severe juvenile dermatomyositis?
23
Citations
2
References
2020
Year
Translational MedicineChildhood ArthritisSevere Juvenile DermatomyositisPathologyClinical DermatologyTherapeutic Decision MakingInterferon SignatureDermatologyDermatopathologyMedicine
| Year | Citations | |
|---|---|---|
Page 1
Page 1